Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19

Set Alert for Coronavirus COVID-19

Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid

More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine. 

COVID-19 Boost As Pharma ROI Hits Heights Not Seen For Seven Years, Finds Deloitte

Expected return on investment for pharma firms jumped sharply to 7% in 2021, driven largely by COVID-19 R&D but even when the pandemic's impact was stripped out, there was an increase in core R&D productivity compared with 2020, a new report from Deloitte has found. The average cost of developing a drug also declined from 2020 to 2021.

Eight COVID-19 Vaccines Approved In India In 2021, mRNA Addition Awaited

While an mRNA vaccine is still missing, 2021 saw Indian companies strike alliances, battle legal action and gain funding while the regulator played a crucial enabling role in the run up to the approval of eight COVID-19 vaccines from zero in 2020.

Vaccine, Antibody Race On As Omicron Spreads In China

An oral vaccine candidate from Hong Kong and domestically-developed antivirals and antibodies join the ongoing development fight as Tianjin city reports new Omicron outbreak.

Xian Under Lockdown, mRNA Vaccines Remain Elusive In China

A relatively large outbreak in another major Chinese city after original epicenter Wuhan heightens the urgency for a more effective mRNA vaccine.

COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022

Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.

BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA

The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.

Coronavirus Update: J&J Shows Promise Against Omicron, UK Nod For Paxlovid

The FDA authorized Comirnaty as a booster shot for 12- to 15-year-olds, as J&J's vaccine has shown effectiveness as a booster in Omicron-dominant settings. Meanwhile, Pfizer's Paxlovid won approval in the UK, and Novavax submitted the final data for its vaccine to the FDA.

More Indian Firms Dip Toes In Vaccines Segment: Just 'Opportunistic'?

The vaccines segment continues to draw the interest of participants beyond those firms with a traditional core presence, with new players largely building partnered capabilities around COVID-19 inoculations. Are these merely opportunistic forays or will the competitive landscape for vaccines stand altered more widely?.

Beximco Delivers First Cut-Price Generic Paxlovid

Bangladesh’s Beximco signed off 2021 on a high launching the first generic version of Pfizer’s Paxlovid at about $186 for a five-day treatment course and claimed that it has ‘adequate capacities' for exports as well.

Kiniksa’s Mavrilimumab Fails In Late-Stage COVID-19 Trial, Doubles Back On Arcalyst

The firm’s anti GM-CSF candidate has underwhelmed in a study in hospitalized COVID-19 patients, triggering renewed focus on its recently launched product Arcalyst for recurrent pericarditis.

How Humira Finally Lost The Top Spot In Drug Sales

AbbVie’s Humira has been the world’s best-selling drug since 2012, and if it hadn’t been for COVID-19 it would most likely have been on track to retain its position for the 10th year in row.

Coronavirus Update: India Approves Multiple New Vaccines

India has issued emergency approvals for a number of new vaccines and extended eligible age groups for others, while developers of potential drug therapies in China see both gains and setbacks. 

Wave Of Molnupiravir Generics In India Amid Early Physician Cheer

India authorizes molnupiravir for restricted emergency use in COVID-19, marking the arrival of around a dozen “affordable” generics of  Merck & Co. and Ridgeback Biotherapeutics' oral antiviral. Physicians say data are “pretty compelling” notwithstanding the narrow FDA nod.

Coronavirus Update: Japan Approves Lagevrio, Korea Clears Paxlovid

Oral antivirals make progress in Asia as Japan issues emergency approval to Merck's Lagevrio in a matter of weeks and South Korea clears Pfizer's contender Paxlovid. Vaccines also move forward in both countries with deals for boosters, new supply agreements and the advancement of home-grown candidates.  

Merck & Co Makes Case For Molnupiravir After Narrow FDA Nod

US regulators have granted emergency authorization to the antiviral molnupiravir but only for use when "alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate."

See All
UsernamePublicRestriction

Register